ESOPJun 10, 2026, 04:22 PM
Syndax Pharma Stockholders Approve 2026 Equity & Employee Stock Plans
AI Summary
Syndax Pharmaceuticals' stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP) at the Annual Meeting on June 10, 2026. The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock, along with shares recycled from the previous 2015 plan, to incentivize employees, directors, and consultants. The 2026 ESPP, a successor to the 2015 ESPP, aims to secure and retain employees by allowing them to purchase company common stock. Additionally, stockholders elected directors, approved executive compensation on an advisory basis, and ratified the selection of the independent auditor.
Key Highlights
- Stockholders approved the 2026 Equity Incentive Plan, effective June 10, 2026.
- The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock, plus recycled shares from the 2015 Plan.
- Stockholders approved the 2026 Employee Stock Purchase Plan (ESPP), effective June 10, 2026.
- The 2026 ESPP is a successor to the 2015 ESPP, with no shares rolling over from the prior plan.
- Directors Pierre Legault and Michael A. Metzger were elected at the Annual Meeting.
- The advisory vote on executive compensation passed with 55,688,039 votes for.
- The selection of the independent registered public accounting firm was ratified with 66,603,912 votes for.
Price Impact
More from SNDX